Last reviewed · How we verify

NCT04182685

Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua

Completed Last updated 4 December 2024
What this trial tests

trial in Zika Virus in 410 participants. Completed in 31 December 2020.

Timeline
1 October 2019
Primary endpoint
31 December 2020
31 December 2020

Quick facts

Lead sponsorRTI International
StatusCompleted
Study typeOBSERVATIONAL
Enrollment410
Start date1 October 2019
Primary completion31 December 2020
Estimated completion31 December 2020
Sites1 location across Nicaragua

Conditions studied

Sponsor

RTI International — full company profile →

Who can join

Adults 5 to 15, any sex, with Zika Virus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Zika virus (ZIKV) infection spread throughout the Americas with devastating consequences. Recent limited evidence suggests the potential for neurological effects associated with postnatally acquired ZIKV infection in humans; however, the impact on children is unknown. The researchers will conduct a longitudinal study of approximately 450 Nicaraguan children who were ages 2-12 in 2016 to evaluate the presence and persistence of neurological symptoms associated with ZIKV infection and to test whether ZIKV-infected children are at greater risk for developing neurological outcomes compared to uninfected children.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other RTI International trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04182685.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing